Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Gene Mutation”

278 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 278 results

Not applicableLooking for participantsNCT04151342
What this trial is testing

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Who this might be right for
CancerMalignancies MultipleMalignant Solid Tumor+7 more
University Health Network, Toronto 5,500
Early research (Phase 1)Looking for participantsNCT06892054
What this trial is testing

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Adenocarcinoma
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 15
Early research (Phase 1)Looking for participantsNCT06484556
What this trial is testing

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Who this might be right for
Tumor, Solid
Tao Zhang 9
Not applicableStudy completedNCT04560270
What this trial is testing

CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

Who this might be right for
Pancreatic CancerCirculating Tumor DNAKRAS Mutation-Related Tumors
Poitiers University Hospital 69
Testing effectiveness (Phase 2)Ended earlyNCT04933695
What this trial is testing

Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Who this might be right for
Non-small Cell Lung Cancer
Amgen 42
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT00655161
What this trial is testing

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Who this might be right for
NSCLC
GlobeImmune 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07554859
What this trial is testing

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Genfleet Therapeutics (Shanghai) Inc. 90
Large-scale testing (Phase 3)Looking for participantsNCT06875310
What this trial is testing

Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc. 630
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Large-scale testing (Phase 3)Study completedNCT02818725
What this trial is testing

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations

Who this might be right for
Infiltrating Urothelial CarcinomaKRAS Gene Mutation
UNICANCER 133
Testing effectiveness (Phase 2)Active Not RecruitingNCT03808558
What this trial is testing

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Who this might be right for
KRAS Gene Mutation
David E Gerber 18
Early research (Phase 1)Active Not RecruitingNCT07474168
What this trial is testing

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Who this might be right for
Tumor
Zhejiang University 9
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Participants With Advanced Solid Tumors

Who this might be right for
Colorectal CancerLung CancerPancreatic Cancer
Beijing DCTY Biotech Co.,Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT01206049
What this trial is testing

Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations

Who this might be right for
Cholangiocarcinoma
Vejle Hospital 88
Testing effectiveness (Phase 2)Looking for participantsNCT07198841
What this trial is testing

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials 48
Testing effectiveness (Phase 2)Ended earlyNCT04165031
What this trial is testing

LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 5
Testing effectiveness (Phase 2)Study completedNCT05375994
What this trial is testing

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerKRAS Activating MutationAdvanced Cancer+3 more
Verastem, Inc. 12
Not applicableStudy completedNCT01124669
What this trial is testing

Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

Who this might be right for
Lung Cancer
ECOG-ACRIN Cancer Research Group 80
Next Page